ArticleCancer medicine2022

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.

Minsuk Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.